Are you above the legal age to view this content in your province/state?

Home / Industry News / Recreational market has apparently impacted on medical cannabis market

Recreational market has apparently impacted on medical cannabis market

Recreational market has apparently impacted on medical cannabis market

Australia, July 8, 2019 (HEMPGAZETTE)- The legalising of cannabis in Canada for the recreational market has apparently impacted on accessibility to medical cannabis – and created other issues.

A survey commissioned by Canadians for Fair Access to Medical Marijuana (CFAMM), the Arthritis Society and the Canadian Pharmacists Association (CPhA) carried out in January this year found a quarter of patients are finding it more difficult to access their cannabis medicines.

“The reality is since legalization it has become easier for recreational users to purchase cannabis than it is for patients to access it through the long-established medical cannabis stream,” states the accompanying release.

Medical Vs. Recreational Marijuana – What’s The Difference?

Medical grade cannabis is subject to more stringent quality control – particularly in relation to achieving consistent specific levels of THC and/or CBD, which is important when it comes to treating or managing a condition. It is more difficult and costly to produce, so manufacturers understandably gravitate to servicing the recreational sector.

That this is happening in Canada isn’t surprising – over the border in the USA, Oregon experienced a similar situation. Oregon  legalized cannabis for recreational use in 2014, and since then the state’s medical cannabis market has tanked.

The potential for the same to happen in Canada was an issue raised prior to recreational use becoming legal back in October last year. Coinciding with legalization was also the introduction of a tax on medical cannabis –  $1 per gram or 10 per cent of the retail price, whichever the greater; putting extra financial stress patients.

According to the organisations, many patients are now buying their “medicine” – and receiving advice – from recreational cannabis outlets – and this creates issues in relation to quality and dosage.

“It’s time the health system treat it as medicine,” said Janet Yale, Arthritis Society President and CEO. “And that starts with ensuring that patients have timely, reliable and affordable access to the strains, forms and concentrations they need, and that they have the guidance of a health care professional throughout the process.”

According to the last published statistics from the Canadian Government, 342,103 patients were registered for medicinal cannabis use as at the end of September last year.

Disclaimer

Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.


Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.


DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.


Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.


Investment Value Finders is intended for those 21+ years of age only!

Check Also

FSD Pharma Talks About Their Expanding Revenue Potential

FSD Pharma Talks About Their Expanding Revenue Potential

Phoenix, Arizona–(Newsfile Corp. – September 12, 2019) – The Stock Day Podcast welcomed FSD Pharma …